

RESEARCH ARTICLE

Open Access

Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

Kurt G Naber^{1*}, Hiltrud Niggemann², Gisela Stein³ and Guenter Stein⁴

Abstract

Background: Nitroxoline, a hydroxyquinoline derivate, has been used for many years to treat urinary tract infections (UTI). Many uncontrolled, but only few controlled clinical studies have been published. Four so far unpublished, controlled clinical studies were meta-analysed.

Methods: A narrative literature review was performed. In addition the individual patient data (IPD) of 466 females with uncomplicated UTI of four prospective, single blind, randomized, clinical studies with similar protocols using nitroxoline (250 mg tid) versus cotrimoxazole (960 mg bid) or norfloxacin (400 mg bid) as controls for 5 days (sporadic UTI) or 10 days (recurrent UTI) were meta-analysed. The primary aim was eradication of bacteriuria 7–13 days after end of therapy (test of cure). Clinical efficacy was determined by elimination of symptoms and safety by adverse events and laboratory tests.

Results: Reviewing a total of 26 uncontrolled, 2 controlled and one postmarketing studies including more than 11,000 patients, good efficacy and safety of nitroxoline could be confirmed. In the four unpublished controlled studies a total of 234 patients were treated orally with nitroxoline and 232 with controls. The safety of nitroxoline was very good and comparable to the controls (adverse events 9.4% vs 7.8%; $p = 0.360$). In the mMITT set (at least one outcome result), in the PP set (test of cure outcome) and in the modified PP set (missing test of cure rated failure) more than 90% of the patients showed eradication of bacteriuria with nitroxoline, which also met statistical non-inferiority compared to the controls (10% non-inferiority margin) in all three evaluation sets. The clinical efficacy was similar between the two treatment groups.

Conclusion: The IPD meta-analysis using objective parameters (elimination of bacteriuria) demonstrated equivalent efficacy (non-inferiority) of nitroxoline with the controls tested (cotrimoxazole, norfloxacin) in the treatment of uncomplicated UTI. Considering the good safety and efficacy of nitroxoline as also shown in many uncontrolled and observational studies and the world wide increase of resistance of uropathogens against cotrimoxazole and fluoroquinolones, but not against nitroxoline within the last 20 years, nitroxoline should be reconsidered as one of the first line antibiotics for the treatment of uncomplicated UTI.

Keywords: Nitroxoline, Cotrimoxazole, Norfloxacin, Uncomplicated urinary tract infection, Meta-analysis

* Correspondence: kurt@nabers.de

¹Department of Urology, Technical University of Munich, Ismaningerstr. 22, 81675 Munich, Germany

Full list of author information is available at the end of the article

Background

Urinary tract infections (UTI) are very frequently found in humans. The most frequent pathogens are *Escherichia coli* and other species of *Enterobacteriaceae*. Gram-positive bacteria, such as staphylococci and enterococci, and non-fermenting Gram-negative bacteria, such as *Pseudomonas aeruginosa*, can also be found [1-4]. Funguria due to *Candida spp.* is mainly cultured in patients with risk factors, e.g. immunocompromised or with infections due to foreign bodies [5,6]. The worldwide increasing bacterial resistance has become a general therapeutic problem. In many countries the resistance rates of *E. coli* against trimethoprim and cotrimoxazole, have exceeded the 20% threshold accepted for empiric therapy by far [1,3,7-9]. Although in many countries still below 20%, the resistance rates of *E. coli* against fluoroquinolones are also increasing worldwide. Therefore, cotrimoxazole, trimethoprim, fluoroquinolones, the former standard therapeutics for uncomplicated UTI [10], but also amoxicillin with and without clavulanic acid and oral cephalosporins are no more recommended in many of the current guidelines as first line antibiotics for the treatment of uncomplicated UTI (cystitis) [11-13]. Older oral antibiotics, such as fosfomycin trometamol, pivmecillinam, and nitrofurantoin, which have still preserved their antibacterial activity against *E. coli* and other uropathogens, are now mostly recommended as first line antibiotics for this indication [11-13]. But further alternatives should be looked for.

Nitroxoline, 5-nitro-8-hydroxyquinoline, has been described first in the fifties of the last century [14]. Since the sixties it has been used for treatment and prophylaxis of acute and recurrent UTI [15,16] in adults and children in the European countries. Nitroxoline is active against most Gram-negative and -positive uropathogenic bacteria [17-19], against mycoplasmas (*M. hominis*, *Ureaplasma urealyticum*) [20,21] and human pathogenic *Candida spp.* [22,23]. The antibacterial activity against *Acinetobacter spp.*, *Enterococcus spp.*, and *Serratia spp.* is variable and *Pseudomonas spp.* are considered resistant [17,19]. Oral treatment with nitroxoline has no qualitative and quantitative effect on the fecal flora [24].

The rate of susceptibility of *E. coli*, the leading uropathogen, at a MIC of nitroxoline of ≤ 8 mg/l is practically 100% and has not changed over the years as shown by a recent in vitro study with 499 strains from patients with community acquired UTI showing MIC₅₀- and MIC₉₀-values of 2 mg/l and 4 mg/l, respectively. The unimodal MIC distribution indicates that these pathogens are wild types without any acquired resistance [25]. For other uropathogens, such as *K. pneumonia*, *P. mirabilis*, *P. vulgaris*, *M. morganii*, and *S. saprophyticus* the MIC₅₀- and MIC₉₀-values were between 4–8/4–8 mg/l with highest MIC of 8 mg/l [26]. The MIC₉₀ for various *Candida spp.*, such as *Candida albicans*,

Candida tropicalis, *Candida parapsilosis*, *Candida krusei*, *Torulopsis (Candida) glabrata*, is between 1 and 4 mg/l nitroxoline [27], which correlate well with other studies [28].

The mode of antibacterial and antifungal action is based on the ability of nitroxoline to chelate with various metallic bivalent cations [29-31]. The antibacterial activity of nitroxoline is decreased by the presence of Mn⁺⁺ and Mg⁺⁺, but not Ca⁺⁺ and univalent ions like Na⁺ and K⁺. The authors assume that magnesium ions stabilizing the lipopolysaccharide (LPS) molecules in the outer bacterial membrane favour the accumulation of nitroxoline in the bacteria, such as *E. coli*. This process is energy independent. Nitroxoline is binding to bacterial surface structures, which probably leads to an interaction between nitroxoline and magnesium ions complexing with LPS phosphate groups [30,31]. The bacterial surface becomes hydrophobic as demonstrated for *E. coli* at 1/8 of MIC of nitroxoline and the adherence to catheter surface is decreased [32]. Nitroxoline inhibits rapidly and selectively RNA synthesis in fission yeast by chelation of bivalent cations required for RNA synthesis [33]. Furthermore, subinhibitory concentrations of nitroxoline have a major inhibitory effect on adhesin expression and bacterial attachment [34-36], which may add an important antibacterial mechanism of nitroxoline. Nitroxoline also reduces the formation and induces the dispersal of *Pseudomonas aeruginosa* biofilms by chelation of iron and zinc [37].

After single oral administration of 200 mg nitroxoline antibacterial urinary activity can be demonstrated by microbiological assays peaking on average between 216 mg/l and 220 mg/l during the urine collection periods 1–2 hours and 3–4 hours [38]. The HPLC concentrations of free nitroxoline, however, were much lower peaking on average between 3.2 mg/l and 5.8 mg/l during that periods. The discrepancy between the two assays was explained by antibacterial active metabolites in urine, because nitroxoline is excreted in the urine in unconjugated as well as conjugated (glucuronide, sulfate etc.) forms [38,39]. A recent study showed that after oral administration of 250 mg about 99% of the excreted nitroxoline was eliminated as metabolites in urine of volunteers, mainly as sulfate and glucuronide, and only 1.0% as the parent component [40,41]. In this study urinary inhibitory and bactericidal concentrations were determined against selected uropathogens, such as *E. coli*, *K. pneumonia*, *P. mirabilis*, and *S. saprophyticus*. In connection with additional urinary bactericidal kinetic studies it was concluded, that nitroxoline exhibits mainly bacteriostatic activity in urine against susceptible strains. Its antibacterial activity is more pronounced in acidic than in alkaline urine.

The aim of this article is to review systematically the available literature on the use of nitroxoline for treatment

and prevention of UTI and to meta-analyse four prospective, randomized, single-blind, multicenter, comparative studies, so far unpublished, in order to improve the evidence based recommendation to use nitroxoline as one of the first line drugs for the treatment of uncomplicated UTI (cystitis).

Methods

Literature search

A narrative literature search concerning efficacy and safety of nitroxoline in the treatment of UTI was performed by the manufacturing company (Rosen Pharma, Blieskastel, Germany). A total of 26 uncontrolled studies including 1206 patients (947 adults and 259 children) published between 1962 and 1987, two controlled studies including 148 patients (100 adult and 48 children) and one postmarketing observational study [42] including 9800 patients with uncomplicated and complicated UTI were found (Tables 1, 2, 3 and 4).

IPD Meta-analysis of four clinical studies

The individual patients' data (IPD) of four prospective, randomized, single-blind, multicenter, comparative studies (data on file, Rosen Pharma GmbH), so far unpublished, were available for this IPD meta-analysis. The four studies were performed to renew marketing registration during December 1992 until 1993 in 20 investigational sites. A total of 466 female patients suffering from acute sporadic cystitis or acute episode of recurrent cystitis was included in the four studies (nitroxoline: n = 234; norfloxacin: n = 54; cotrimoxazole: n = 178). For the meta-analysis the original individual patient's data (IPD) could be analyzed.

The studies were performed in accordance with the declaration of Helsinki updated in Hongkong 1989 [69]. Before start they were voted positively by the Ethical Commissions of the Medical Councils of Saarland for study NWNF #10 (dated 7 Sept 1992), Bavaria for study NWNF #11 (dated 20 October 1992, Nr. 92247), Rheinland-Pfalz for study NWNF #13 (dated 3 November 1992), and Hessen for study NWNF # 15 (dated 2 November 1992, Nr. 71/92), and the respective countries of Germany

Table 1 Total number (n) of published clinical studies on treatment of urogenital infections with nitroxoline as found by the narrative literature search

Study design	Population	Studies (n)	Patients (n)
Uncontrolled	Adults	15	947
Uncontrolled	Children	11	259
Controlled vs. norfloxacin	Adults	1	100
Controlled vs. TMP/SMX	Children	1	48
Observational	Adults	1	9,800
Total		29	11,154

TMP/SMX – trimethoprim/sulfamethoxazole.

where the studies were performed. A registration in a public trials registry was not required at that time.

Study design

The four clinical studies were prospective, randomized, single-blind (patient blinded), multicenter, and comparative in parallel groups. The aim of the studies was to compare the efficacy and safety of nitroxoline versus cotrimoxazole and norfloxacin in female patients with acute uncomplicated sporadic cystitis (NWNF 10, 11, 13) or with acute episode of recurrent uncomplicated cystitis (NWNF 15). In Table 5 the main parameters of the design of the four studies are outlined.

Selection of patients

After medical history including kind and duration of symptoms, pretreatment and concurrent medication, physical examination including body temperature, urinalysis and confirmation of the clinical diagnosis including additional tests needed, eligible patients were informed about aim, performance, possible adverse events and their right to terminate the study without giving any reasons. If written informed consent was documented, patients were included into the study after inclusion and exclusion criteria had been checked.

In three studies (NWNF 10, 11, 13) female patients with clinical signs and symptoms of acute sporadic uncomplicated cystitis and in one study (NWNF 15) those with acute episode of recurrent uncomplicated cystitis were included. In all patients a pretreatment midstream or single catheter urine sample was requested to show pyuria (white blood cells >5 000/ml) and bacteriuria with colony forming units (CFU) $\geq 10^5$ /ml due to susceptible pathogens.

According to the study protocol exclusion criteria were: age below 18 years; taking part in a clinical study during the last 30 days; pregnancy; urolithiasis or obstruction within the urinary tract; severe systemic, gastrointestinal, kidney or liver diseases; hypertension; diabetes mellitus; known erythema exsudativum multiforma, pathologic hemogram including hemoglobin anomalies; glucose-6-phosphate-deficiency; acute porphyria; folic acid deficiency; known seizure disorder; and allergy against sulfonyl urea antidiabetics and sulfonamide based diuretics.

Randomization, treatment, and visits

Female patients were randomized in two age groups (upto 45 and above 45 years) and received their allocated antibiotic wrapped in a neutral box signed "for clinical study only". Because an objective outcome (eradication of bacteriuria) was the primary aim of the study, a double-blind design was not considered necessary at that time.

Table 2 Fifteen uncontrolled clinical studies with nitroxoline in 947 adult patients of both genders

First author	Year	Pat (n)	Indication (T/P)	Dosage	Duration	Success rate	Adverse events
Kuss [43]	1962	72	T: acute cUTI & uUTI	400 mg/d	20–45 days	78%	1.3% gastrointestinal
Moreau [44]	1962	20	T: acute cUTI	400–500 mg/d	8–10 (–45) days	90%	5% gastrointestinal
v. Rütte [45]	1969	200	P: chronic rUTI	300–500 mg/d shortly 800 mg/d	2–3 months 1 day	80%	0%
Uhlir [46]	1972	20	T: acute UTI (7), chronic PN (13)	300 mg/d	14 days	100%	0%
Allal [47]	1973	264	T: UTI during pregnancy	300 mg/d	6 days	> 75%	No data
Bittard [48]	1974	50	P: post-op. catheter	7.5–10 mg/kg/d	6 weeks	92%	Few gastrointestinal
Schlesinger [49]	1975	65	T: chronic PN (62), chronic prostatitis (3)	300–500 mg/d	10 days	80% clinical	0%
Aubert [50]	1976	28	T: post-op. catheter, after endoscopy	200–300 mg/d	10–15 days	72%	0%
Dufour [51]	1979	15	T: acute prostatitis	900–1600 mg/d	3–5 days	81%	No data
Lenzner [52]	1983	60	T: fungal UTI	750 mg/d	10–20 days	80%	3.3% itching; few cases with nausea and vomiting
Schülke [53]	1984	50	T: postop., acute UTI after removal of urethral catheter for 3–10 days	750 mg/d	3 days	78%	0%
Sachse [54]	1984	44	P: chronic rUTI	750 mg/d	4 months	77% free of rUTI; rUTI rate decreased from 0.33 to 0.11/month	9% gastrointestinal 2.2% exanthema
Demontrond [55]	1986	15	T: candiduria in hospitalised patients	600 mg/d	10–30 days	87%	0%
Frobert [56]	1987	36	T: acute, uUTI in hospitalised patients	600 mg/d	10 days	93% bacteriological 87% clinical	5.5% gastrointestinal 2.7% nausea 2.7% dizziness
Cancel [27]	1987	8	T: urogenital fungal infections	600 mg/d	15 days	100%	no data

T-therapy; P-prophylaxis; UTI-urinary tract infection; uUTI-uncomplicated UTI; cUTI-complicated UTI; PN-pyelonephritis.

Patients in the nitroxoline group were asked to take one capsule containing 250 mg nitroxoline three times daily with the three main meals. Patients of the control group were asked to take one tablet containing 960 mg cotrimoxazole (NWNF 10, 11, 15) or 400 mg norfloxacin (NWNF 13) twice daily with the morning and evening meal. The treatment duration was 5 days in 3 studies (NWNF 10, 11, 13) and 10 days in one study (NWNF 15). The control visits were one day (end of treatment) and 7–13 days (test of cure) after end of therapy. In the ten day treatment study (NWNF 15) an additional visit during therapy at day 6 was scheduled.

Primary objectives The primary objective was the eradication (CFU <10⁴/ml) of the bacteriuria due to susceptible pathogens at test of cure in compliant patients (≥80% of medication) without taking any additional antibiotic.

Secondary objectives Secondary objectives were clinical efficacy and safety. For clinical efficacy the following symptoms were scored (0-absent upto 5-very severe) by the patient: dysuria, frequency, urgency, nycturia, flank/back pain. The clinical efficacy was assessed also globally by the patient and the investigator. At each visit patients were asked for any adverse event, which was documented. The safety was assessed also globally by the patient and the investigator.

The following laboratory tests were performed: Urinalysis (white and red blood cells, nitrite reaction, protein, glucose, pH), serum chemistry (glucose, creatinine, bilirubin, AST, ALT, gammaGT, sodium, potassium, calcium) and hematology (red and white blood count, thrombocytes, blood sedimentation rate).

Evaluation sets

The efficacy and safety was analysed in the following patients' sets:

Table 3 Eleven uncontrolled clinical studies on treatment and prophylaxis of UTI with nitroloxline in 259 children

First author	Year	Patients (n)	Indication (T/P)	Dosage	Duration	Success rate	Adverse events
Lecornu [57]	1974	25 children 0–13 years	T: compl. and uncompl. UTI	50–400 mg/d as suspension	4–12 days	72%	8% nausea
Roussel [58]	1974	24 children 7 days–6 months	T: compl. and uncompl. UTI	10 mg/kg/d as suspension	10 days- 6 months	79%	0%
Raynaud [59]	1974	19 children 0–10 years	T: compl. and uncompl. UTI	10 mg/kg/d as suspension	20 days	69%	10% nausea
Luckel [60]	1975	25 children 0–8.5 years	P: compl. and uncompl. UTI	10–20 mg/kg/d as suspension	17–55 days	83%	0%
Viville [61]	1975	22 children 2 months-17 years	P: compl. UTI	10–30 mg/kg/d as suspension	3–6 months	86%	0%
Chable [62]	1975	28 children 2 month-14.5 years	T: compl. and uncompl. UTI	10–20 mg/kg/d as suspension	10 days	81%	0%
Battin [63]	1975	30 children 2 month-10 years	P: compl. and uncompl. UTI	10 mg/kg/d as suspension	6 weeks	90%	0%
Sorez [64]	1975	30 children 10 days-8 years	T: compl. and uncompl. UTI	10–25 mg/kg/d as suspension	10 – 17 days	73.7% uncompl. UTI 40% compl. UTI	0%
Neimann [65]	1975	21 children 26 days-8 years	T/P: compl. and uncompl. UTI	25–400 mg/d as suspension	4 days-4 months	90%	10% nausea
Machecourt [66]	1976	23 children 21 days-14 years	T: compl. and uncompl. UTI	10–20 mg/kg/d as suspension	10 days	91%	0%
Lambert-Zechovsky [24]	1987	12 children aver. 4 years	T: uncompl. UTI	20 mg/kg/d as suspension	10 days	66% (91% incl. non-compliance)	-

n-number; T-therapy; P-prophylaxis; UTI-urinary tract infection.

Table 4 Two controlled open clinical studies in a total of 148 patients with nitroxoline (NTX) versus norfloxacin (NFX) or cotrimoxazole (CTX); SMX-sulphamethoxazole; TMP-trimethoprim

First author	Year	Pat.(n)	Indication (T/P)	Antibiotic and dosage	Duration	Success rate	Adverse events
Schülke [67]	1986	51 NTX 49 NFX	T: postop., uncompl. UTI	750 mg NTX/d vs. 800 mg NFX/d	3 days	60.8% NTX 59.2% NFX	0%
Dodat [68]	1988	48 children 0–8 years	P: postop. UTI (ureteral reflux)	10 mg NTX/kg/d vs. 15 mg SMX/ 3 mg TMP/kg/d	30–60 days	95% NTX 95% CTX	6% NTX 5% CTX

T-therapy; P-prophylaxis, UTI-urinary tract infection.

Safety set: All patients included into the study having received any study medication.

Modified microbiologically Intention-to-Treat Set (mMITT): All patients with significant bacteriuria (CFU $\geq 10^5$ /ml) at study entry; with at least one control visit including microbiological investigation, and with a consistent clinical report (in study NWNF 10 few clinical reports were inconsistent). The last observation was brought forward (LOF), if not failure has already been documented and an additional antibiotic been administered.

Per Protocol Set (PP): All patients with significant bacteriuria (CFU $\geq 10^5$ /ml) at study entry; with test of cure visit including microbiological investigation (except failure was already documented and additional antibiotic administered); doubtless randomization; and compliance ($\geq 80\%$ of allocated drug).

Modified per Protocol Set (mPP): All patients with significant bacteriuria (CFU $\geq 10^5$ /ml) at study entry; with test of cure visit including microbiological investigation; missing test of cure visit was rated as failure (worst case) [70]; doubtless randomization; and compliance ($\geq 80\%$ of allocated drug).

Statistical analysis

The individual patient data were entered and independently checked to ensure high data quality. Categorical data are described by absolute and relative frequencies. Ordinal data are either described in tables by absolute and relative frequencies (global clinical assessment) or by box plots (scoring of clinical symptoms). For numerical data median as well as minimum and maximum value are given.

To evaluate the noninferiority of nitroxoline compared to the controls with regard to the failure rate the difference of the failure rates of the two treatments and its 95%-confidence interval is estimated [71]. Odds Ratios are estimated, too. Difference as well as odds ratio are estimated by logistic regression with random center effect [72]. Since the proportion of variance explained by the centers exceeded substantially the proportion of variance explained by the four studies random center effects instead of random study effects were added to the model. Whether the distribution of ordinal data is the same in the two treatment groups is analyzed by ordered probit regression, the distribution of numerical data is compared by linear regression. For both approaches random center effects are taken into account.

Table 5 Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)

Study	Nitroxoline	Control	Indication	Patients (n)	Duration	End of therapy visit	Test of cure visit
NWNF 10*	Nitroxoline (NTX) 3x250 mg	Cotrimoxazole (CTX) 2x960 mg	Acute uncompl. cystitis	130 total 67 NTX, 63 CTX	5 days	day 6	day 12–14
NWNF 11	Nitroxoline (NTX) 3x250 mg	Cotrimoxazole (CTX) 2x960 mg	Acute uncompl. cystitis	115 total 56 NTX 59 CTX	5 days	day 6	day 12–14
NWNF 13	Nitroxoline (NTX) 3x250 mg	Norfloxacin (NFX) 2x400 mg	Acute uncompl. cystitis	105 total 51 NTX 54 NFX	5 days	day 6	day 12–14
NWNF 15	Nitroxoline (NTX) 3x250 mg	Cotrimoxazole (CTX) 2x960 mg	Acute episode of uncompl. recurrent cystitis	116 total 60 NTX 56 CTX	10 days	day 11–13*	day 21–23

*inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).

*additional visit during therapy: day 6–8.

All p-values are two-sided, the level of significance is set to 0.05. Stata/IC 13.1 was used for data preparation and statistical analysis.

Results

Literature search

The 26 uncontrolled clinical studies published between 1962 and 1987 included a total of 1206 patients (947 adults and 259 children) (Table 1). Nitroxoline was mainly administered for treatment of uncomplicated and complicated UTI as well as for prophylaxis of recurrent UTI with daily dosages mostly between 300 and 900 mg. The treatment duration varied mainly between 3 and 10 days depending on the indication. Study details are presented in Tables 2 and 3.

The summary results of the two controlled studies including 148 patients (100 adult and 48 children) are outlined in Table 4. In one study 51 patients received 250 mg nitroxoline tid versus 49 patients 400 mg norfloxacin bid for treatment of postoperative and uncomplicated UTI [67]. The microbiological outcome was comparable in both groups (about 60%); no adverse events were reported. The second controlled study was performed in 48 children with ureteral reflux [68]. The children received either nitroxoline or cotrimoxazole for prophylaxis of UTI for 30–60 days. In 95% of the children a recurrent UTI could be prevented in both groups. Adverse reactions were reported in 6% with nitroxoline and in 5% with cotrimoxazole.

The postmarketing observational study included 9800 patients (75% women, 25% men) with complicated and uncomplicated UTI including recurrent UTI, and to a lesser extent also with fungal urogenital infections [42]. The dosage of nitroxoline was fixed at 250 mg tid, but the treatment duration was chosen according to the physician's decision. The physician's assessment revealed clinical success of 95% in cystitis, 79% in recurrent and complicated UTI; 80% in pyelonephritis, and 91% in fungal infections. The overall patient's assessment of success was 95%. Only 2.2% of the patients reported adverse events overall including 1.8% gastrointestinal and 0.3% allergic adverse events.

IPD meta-analysis

Patients

The studies were performed in 20 German cities from Dezember 1992 until 1993. A total of 466 female patients (nitroxoline: n = 234, controls: norfloxacin: n = 54; cotrimoxazole: n = 178) was included in the four clinical studies. In the IPD meta-analysis the results obtained from patients in the nitroxoline group were compared with those obtained from patients in the control groups, norfloxacin and cotrimoxazole.

Demography, history and physical examination

In Table 6 some data concerning demography, history and physical examination are compared between nitroxoline and controls in the safety set. A significant difference was only found as a slightly higher body mass index, higher systolic blood pressure and a lower proportion pre-treated by antibiotics in the group of the controls. Both groups included about the same number of patients upto 45 and above 45 years. Although diabetes mellitus and hypertension, considered as exclusion criteria in the original protocol, was found in some patients in both groups, these patients were not excluded from the meta-analysis, because these underlying diseases were considered only minor protocol violations.

Flow of patients

In Figure 1 the total number of patients included in the studies is shown, randomized to nitroxoline and controls and excluded because of different reasons from the evaluation sets. Finally the safety (mMITT/mPP/PP) set comprised 234 (211/205/200) patients in the nitroxoline and 232 (213/210/206) in the control groups.

Quality of the studies

Each of the four randomized clinical trials achieved a good quality with four out of maximum five Jadad scores [73,74]: randomization (1 score), which was appropriate (1 score), patient blinding only (0 score), which was appropriate (1 score), and drop-outs well-grounded (1 score).

Bacterial spectrum and resistance to study drugs

The bacterial spectrum and resistance at study entry (visit 1) is shown in Table 7. On average about 10% of the patients were included with mixed infections. Therefore the total number of isolates were higher than the number of patients included. *Escherichia coli* was the most frequent pathogen in all studies ranging from 65% to 73% of all isolates. The percentages of resistant isolated to nitroxoline ranged from 0% to 5.5% and that to the control antibiotics from 0.8% to 5.2%. There was no evidence, that patients with recurrent UTI (study NWNF 15) showed more resistant strains than patients with sporadic UTI (studies NWNF 10,11,13).

Microbiological outcome

The microbiological outcome (eradication of bacteriuria $<10^4$ /ml) as primary study aim is shown in Table 8. In all three evaluation sets the eradication rates were above 90% in the nitroxoline and in the control groups. The 95% confidence intervals (CI) of the estimated eradication rate differences met statistical non-inferiority compared to the controls (10% non-inferiority margin) in all three evaluation sets.

Figure 2 shows the 95% CI of the individual studies and the total result of the four meta-analysed studies

Table 6 Demography, history, and physical parameters of female patients investigated in the safety set


Demographic parameter	Nitroxoline		Controls		p-value
	n	Median (range)	n	Median (range)	
Age (years)	234	48 (18–89)	232	47 (18–85)	0.520
-up to 45 years	234	113 (48.3%)	232	115 (49.6%)	0.745
Height (cm)	234	165 (150–185)	231	165 (145–187)	0.290
Weight (kg)	234	62 (43–100)	232	64 (42–102)	0.125
Body mass index (kg /m ²)	234	23.0 (15.9–41.3)	231	23.2 (15.6–38.0)	0.038
Heart rate (min ⁻¹)	231	80 (52–172)	231	80 (56–120)	0.354
Systolic BP (mmHg)	232	120 (80–195)	231	130 (100–190)	0.025
Diastolic BP (mmHg)	232	80 (60–120)	231	80 (50–120)	0.410
No hypertension (SBP ≤ 140 mmHG)	232	165 (71.1%)	231	137 (59.3%)	0.004
Mild hypertension (SBP > 140 mmHG)	232	46 (19.8%)	231	63 (27.3%)	
Moderate hypertension (SBP > 160 mmHG)	232	17 (7.3%)	231	22 (9.5%)	
Severe hypertension (SBP > 180 mmHG)	232	4 (1.7%)	231	9 (3.9%)	
Diabetes mellitus	234	11 (4.7%)	232	6 (2.6%)	0.230
Duration of urinary symptoms (d)	165	3 (1–30)	168	3 (1–21)	0.442
Pretreatment with antimicrobials*	234	16 (6.8%)	232	8 (3.4%)	0.060
Only unspecific pretreatment [#]	234	25 (10.7%)	232	28 (12.1%)	0.667

*antibiotics, chemotherapeutics.
[#]spasmolytics, analgetics, tea etc.

together in the mMITT and the PP sets with the contributing weight of each study.

The eradication rates of *E. coli* in mono and mixed infection and Non-*E. coli* mono and mixed infections in the PP set are shown in Table 9. As expected about 80%

(79.0% vs 79.6%) of the patients in both groups had an *E. coli* infection either as mono or mixed infection with overall eradication rates of 94.3% and 96.3%, respectively. In the about 20% Non-*E. coli* infections the overall eradication was 83.3% and 93.0% in the nitroxoline and the control groups, respectively.



Clinical efficacy

In Figure 3 the clinical efficacy in the PP sets are presented as reduction of symptoms as scored pre- and post-treatment. At the end of therapy no significant differences were seen in dysuria (pain during micturition), nocturia and flank/back pain between the two groups. Marked reductions of frequency (pollakisuria) and urgency (imperative micturition) were also seen (included) in both groups, which were, however, more pronounced in the controls. Considering the overall low scores achieved at the end of therapy, the differences may not be clinical relevant.

Global clinical assessment

In the global clinical assessment (Table 10) the patient (investigator) rated the treatment with nitroxoline in 91.2% (90.5%) and that with the control antibiotics in 96.2% (95.5%) as very good or good.

Safety

The treatments with nitroxoline and the control antibiotics were generally well tolerated (Table 11). A total of 9.8% treated with nitroxoline and 7.8% treated with a control

Table 7 Bacterial spectrum and resistance (R) against nitroxoline (Ni) versus controls (C), cotrimoxazole or norfloxacin, at study entry (visit 1)

Study Nr./R	NWNF 10	R(n)	NWNF 11	R(n)	NWNF 13	R(n)	NWNF 15	R(n)	NWNF 10-13	R(n)	NWNF 10-15	R(n)
Bacterial isolates	n (%)	Ni/C	n (%)	Ni/C	n (%)	Ni/C	n (%)	Ni/C	n (%)	Ni/C	n (%)	Ni/C
<i>E. coli</i>	82(67.2%)	-/1	88(65.3%)	1/6	81(67.0%)	-/-	98(73.0%)	-/-	251(66.4%)	1/7	349(68.2%)	1/7
<i>Proteus spp.*</i>	20(16.4%)	-/-	9(6.7%)	-/-	8(6.6%)	-/-	12(9.0%)	-/-	37(9.8%)	-/-	49(9.6%)	-/-
<i>Klebsiella spp.</i>	1(0.8%)	-/-	5(3.7%)	-/-	1(0.8%)	-/-	6(4.5%)	-/-	7(1.9%)	-/-	13(2.5%)	-/-
<i>Enterobacter spp.</i>	-	-	2(1.5%)	-/-	3(2.5%)	-/-	7(5.2%)	-/2	5(1.3%)	-/-	12(2.3%)	-/2
<i>Citrobacter spp.</i>	2(1.6%)	-/-	-	-/-	1(0.8%)	-/-	1(0.8%)	-/-	3(0.8%)	-/-	4(0.8%)	-/-
Enterococci	9(7.4%)	-/-	13(9.7%)	6/1	13(10.7%)	-/1	2(1.5%)	-/-	35(9.3%)	6/2	37(7.2%)	6/2
Staphylococci	5(4.1%)	-/-	7(5.2%)	-/-	13(10.7%)	1/-	8(6.0%)	-/-	25(6.6%)	1/-	33(6.4%)	1/-
Streptococci	2(1.6%)	-/-	2(1.5%)	-/-	1(0.8%)	-/-	-	-/-	5(1.3%)	-/-	5(1.0%)	-/-
Others	1(0.8%)	-/-	9(6.7%)	-/-	-	-/-	-	-/-	10(2.6%)	-/-	10(2.0%)	-/-
Total	122 (100%)	-/1	135 (100%)	7/7	121 (100%)	1/1	134 (100%)	-/2	378(100%)	8/9	512(100%)	8/11
		-/0.8%		5.2/5.2%		0.8/0.8%		-/1.5%		2.1/2.4%		1.6/2.1%
Isolates/patients	122/122 (1.0)		135/115 (1.17)		121/105 (1.15)		134/116 (1.16)		378/350 (1.08)		512/466 (1.1)	

*indol positive and negative strains.

antibiotic reported any adverse event ($p = 0.360$). Only 5 (nitroxoline 3; controls 2) patients discontinued the treatment prematurely because of adverse events. The main adverse events were gastrointestinal disorders (nitroxoline 19; controls 9). In 3 patients of each group allergic reactions including itching, urticaria and in one case with papules/pustules (nitroxoline) were seen.

In the laboratory parameters (Table 12) no significant differences between critical values were observed between the two treatment groups (nitroxoline/controls), except a higher pretreatment (12.8% vs. 6.4%), but not posttreatment rate of critical values regarding the number of blood erythrocytes in the nitroxoline group.

Discussion

When nitroxoline was first marketed in the European Union in 1962 for treatment and prophylaxis of UTI, microbiological and observational studies were considered sufficient. For this reason between 1962 and 1987 only uncontrolled studies were published not only for treatment

and prophylaxis of uncomplicated, but also for treatment of complicated UTI including pyelonephritis, prostatitis and fungal infections in adults of both genders, and also in children. Only two prospective randomized studies, one for treatment of uncomplicated UTI in adults and one for prophylaxis of UTI in children, were published, both with low number of patients [67,68]. Although these studies may not be considered highly evidential, they can at least contribute to establish the safety of nitroxoline in adults as well as in children together with the large postmarketing observational study.

When the requirements became more stringent for the renewal of the regulatory approval, finally achieved in Germany in 2005, four prospective randomized single blind studies were performed during 1992 and 1993 with cotrimoxazole and norfloxacin as controls. All four studies followed in essence the same protocol with the only difference that the treatment duration in women with sporadic uncomplicated UTI was five days and in women with acute episode of recurrent

Table 8 Microbiological success (eradication of bacteriuria) in the different evaluation sets

Evaluation set	Nitroxoline	Controls	Difference (%) (95%-CI)	Odds ratio (95%-CI)
mMITT	192/211 (91.0%)	203/213 (95.3%)	-3.4 (-9.7 to 3.0)	0.47 (0.21 to 1.06)
PP	184/200 (92.0%)	197/206 (95.6%)	-2.2 (-8.2 to 3.7)	0.47 (0.19 to 1.14)
mPP	185/205 (90.2%)	197/210 (93.8%)	-2.9 (-9.9 to 4.1)	0.60 (0.28 to 1.27)

mMITT-modified microbiological intention to treat; PP-per protocol; mPP-modified per protocol.

Difference: nitroxoline - controls.

Odds Ratio: nitroxoline vs controls.

Estimation by logistic regression with random center effect.




Figure 2 Estimated difference (95%-confidence interval) between the microbiological success and weights from random effects analysis in the mMITT-Set and PP-Set of patients treated with nitroxoline as compared to controls in the four studies analysed. mMITT-modified microbiological intention to treat; PP-per protocol.

UTI was ten days. All four studies were of high quality achieving four out of maximum five Jadad scores [73,74]. The bacterial spectra were similar between the studies with *E. coli* as most frequent pathogen ranging from 65% to 73%. There was no evidence that females

suffering from recurrent UTI showed more resistant strains than those with sporadic UTI. During the years 1992–1993, when the studies were performed, the resistance rates for cotrimoxazole and norfloxacin were still very low. Both antibiotics were considered first

Table 9 Microbiological success (eradication of bacteriuria) according to bacterial groups in the PP set

	Nitroxoline	Controls
Monoinfection <i>E. coli</i>	129/138 (93.5%)	141/145 (97.2%)
Mixed infection <i>E. coli</i>	20/20 (100%)	17/19 (89.5%)
Monoinfection with Non- <i>E. coli</i>	28/34 (82.4%)	37/40 (92.5%)
Mixed infection with Non- <i>E. coli</i>	7/8 (87.5%)	2/2 (100%)
Total	184/200 (92.0%)	197/206 (95.6%)

line drugs for the treatment of uncomplicated UTI at that time [10]. For all these reasons, including the data of all four studies in one meta-analysis was justified.

Since the clinical report forms (CRF) of the individual patients were available, an IPD meta-analysis could be performed, a specific type of systematic review [75]. Rather than extracting summary (aggregate) data from study publications, the original research data are sought directly for each study. These data can then be re-analysed centrally and combined, if appropriate, in meta-analyses. IPD meta-analyses can improve the quality of data and their analysis and thus produce more reliable results [76]. For this reason they are considered a 'gold standard' of systematic review in contrast to meta-analyses of aggregate data, which relates to information averaged or estimated across all individuals in a study. In a two step approach the individual participant data are first analysed in each separate study independently and then synthesized using a suitable model for meta-analysis of aggregate data. With individual participant data an analytic standardisation across the studies and a direct derivation of the information requested is possible, independent of significance or how it was reported.

Since at that time the microbiological evaluation was the primary aim practically in all UTI studies, a single-blind design was considered sufficient, because the eradication (primary aim) could be determined in an objective manner. Nevertheless, from today's point of view the single-blind design could be considered as a weakness of the studies, which may have affected mainly the clinical outcome and some subjective adverse events. However, the non-inferiority of nitroxoline for the eradication of bacteriuria as compared to the controls, cotrimoxazole and norfloxacin, is fairly well established by this IPD meta-analysis, whereas the individual studies contributed each between about 20 and 30% to the final results. Another shortcoming of the study may be, that after the test of cure the patients were not followed for a longer time. Therefore no information is available concerning the relapse rate after the test of cure visit.

Since the final microbiological evaluation in UTI studies is usually not performed at the end of treatment, but rather after the antibiotic substances are completely




Table 10 Global clinical assessment by the investigator in the PP set (no assessment in 103 patients)

Assessment Group	Investigator		Patient	
	Nitroxoline (n = 148)	Controls (n = 158)	Nitroxoline (n = 148)	Controls (n = 158)
Very good	115 (77.7%)	138 (87.3%)	109 (73.6%)	123 (77.8%)
Good	19 (12.8%)	13 (8.2%)	26 (17.6%)	29 (18.4%)
Satisfactory	4 (2.7%)	5 (3.2%)	5 (3.4%)	4 (2.5%)
Moderate	1 (0.7%)	0 (0%)	3 (2.0%)	1 (0.6%)
Insufficient	9 (6.1%)	2 (1.3%)	5 (3.4%)	1 (0.6%)
p-value*	0.006		0.143	

*comparison of nitroxoline vs. controls (ordered probit regression with random center effect).

eliminated from the urinary tract and uropathogens, still present, have had time to multiply to significant numbers, the usual ITT and PP analyses may benefit good results, when patients drop out with favourable results after the end of treatment visit. These patients are considered a

microbiological cure in the ITT set (last observation brought forward) and are drop outs for the classical PP analysis. Thus, possible treatment failures will be not recorded, because usually the reasons for dropping out after the treatment visit remains unknown. Therefore,

Table 11 Adverse events

Adverse events (AE)		Nitroxoline	Controls
	Patients (total)	234 (100%)	232 (100%)
	Patients with AEs [#]	23 (9.8%)	18 (7.8%)
Adverse events (total)		33	26
Nervous system disorders	Headache	3	4
	Dizziness	-	3
Eye disorders	Eyelid swelling	1	-
Cardiac and circulation disorders	Circulation disorder	-	1
Gastrointestinal disorders	Dysgeusia	-	1
	Nausea	9	3
	Regurgitation	1	1
	Gastralgia	4	3
	Obstipation	-	1
	Diarrhoea	5	-
Metabolim and nutrition disorder	Anorexia	1	-
Urinary disorders	Incontinence	1	-
Reproductive system disorders	Colpitis	1	1
	Fluor vaginalis	1	-
	Tubal tumor	-	1
Immune system disorders	Allergy	1*	1
Skin and subcutaneous tissue disorders	Itching	1	1
	Urticaria	1	1
	Herpes labialis	-	1
General disorders	Intolerance	1	-
	Weakness	1	-
	Fever	1	-
Musculoskeletal, connective tissue and bone disorders	Back pain	-	1
	Flank pain	-	2
	Leg pain	-	1

[#]comparison of nitroxoline vs. controls (logistic regression with random center effect) p = 0.360; *with papules/pustules.

Table 12 Laboratory parameters before and after treatment in the safety-set

	Critical values	Pretreatment			Posttreatment		
		Nitroxoline	Controls	p-value*	Nitroxoline	Controls	p-value*
Glucose (mg/dl)	< 55, >160	20/227 (8.8%)	12/226 (5.3%)	0.138	12/206 (5.8%)	7/207 (3.4%)	0.242
Creatinine (mg/dl)	> 1.8	1/228 (0.4%)	1/227 (0.4%)	0.998	1/205 (0.5%)	0/207 (0%)	-
Bilirubin (mg/dl)	< 0.1, >2.0	3/226 (1.3%)	1/227 (0.4%)	0.337	2/205 (1.0%)	4/207 (1.9%)	0.426
SGOT –AST (U/l)	< 35, >= 150	224/226 (99.1%)	225/226 (99.6%)	0.570	203/205 (99.0%)	206/207 (99.5%)	0.564
SGPT - ALT (U/l)	< 35, >= 150	222/226 (98.2%)	225/226 (99.6%)	0.212	204/205 (99.5%)	207/207 (100%)	-
gamma-GT (U/l)	< 3, >38	9/227 (4.0%)	10/226 (4.4%)	0.807	9/205 (4.4%)	6/207 (2.9%)	0.412
Sodium (mmol/l)	< 130, >150	8/228 (3.5%)	6/226 (2.7%)	0.603	11/205 (5.4%)	5/207 (2.4%)	0.132
Potassium (mmol/l)	< 3.6, >6.0	22/228 (9.6%)	19/226 (8.4%)	0.628	19/205 (9.3%)	12/206 (5.8%)	0.229
Calcium (mmol/l)	< 8, >11.5	229/229 (100%)	227/227 (100%)	-	206/206 (100%)	206/206 (100%)	-
Hemoglobin (g/dl)	< 10, >17	0/227 (0%)	0/219 (0%)	-	1/201 (0.5%)	2/204 (1.0%)	0.582
Hematocrit (%)	< 32, >47	25/227 (11.0%)	33/220 (15.0%)	0.197	20/201 (10.0%)	33/204 (16.2%)	0.065
Erythrocytes (Mio/ μ l)	< 4, >5.1	29/227 (12.8%)	14/220 (6.4%)	0.024	22/201 (10.9%)	26/205 (12.7%)	0.588
Leucocytes (Tsd/ μ l)	< 4, >11.3	25/227 (11.0%)	21/220 (9.5%)	0.605	13/200 (6.5%)	16/204 (7.8%)	0.614
Neutrophiles (%)	< 39, >75	22/225 (9.8%)	37/221 (16.7%)	0.031	15/199 (7.5%)	13/203 (6.4%)	0.656
Eosinophiles (%)	< 1, >10	10/223 (4.5%)	19/219 (8.7%)	0.080	11/199 (5.5%)	8/203 (3.9%)	0.399
Basophiles (%)	0, >15	38/222 (17.1%)	47/220 (21.4%)	0.257	29/199 (14.6%)	38/203 (18.7%)	0.266
Lymphocytes (%)	< 10, >50	9/221 (4.1%)	12/220 (5.5%)	0.391	7/198 (3.5%)	11/203 (5.4%)	0.382
Monocytes (%)	< 3, >25	7/223 (3.1%)	14/220 (6.4%)	0.117	9/199 (4.5%)	6/203 (3.0%)	0.410
Retikulocytes (%)	< 0.5, >2	220/224 (98.2%)	212/218 (97.2%)	0.493	198/200 (99.0%)	200/205 (97.6%)	0.227
Thrombocytes (Tsd/ μ l)	< 150, >450	11/225 (4.9%)	8/218 (3.7%)	0.529	10/201 (5.0%)	8/204 (3.9%)	0.608
BSR (mm/1 h)	< 5, >11	134/203 (66.0%)	124/202 (61.4%)	0.343	106/179 (59.2%)	114/187 (61.0%)	0.756
BSR (mm/2 h)	> 25	82/202 (40.6%)	88/200 (44.0%)	0.470	44/178 (24.7%)	57/186 (30.6%)	0.207

BSR-blood sedimentation rate.

*comparison of nitroxoline vs. controls, logistic regression with random center effect.

a modified PP set was evaluated, in which all patients dropping out before test of cure were considered treatment failure (worst case scenario). Only if the same results can be achieved in all three evaluation sets, the overall result (non-inferiority) can be taken as proven, which was established by this IPD meta-analysis for nitroxoline as compared to the controls.

The current guidelines do usually not recommend a longer treatment duration of an acute episode in women with recurrent UTI than in those with sporadic UTI any more. For cotrimoxazole and fluoroquinolones even a 3-day therapy is considered sufficient in acute uncomplicated cystitis, but for the usage of macrocrystal nitrofurantoin also a 5-day therapy is recommended in the current guidelines [11-13]. Therefore a 5-day therapy of nitroxoline 250 mg tid should also be recommended as one of the first line options for the treatment of acute uncomplicated UTI (cystitis). Since about half of the female patients were pre- and postmenopausal in the studies meta-analysed, the dosage regimen and duration for both female groups can be considered the same, because in current guidelines an acute cystitis in otherwise

healthy postmenopausal women is also considered as uncomplicated [12].

Conclusions

Nitroxoline used for more than 50 years for the treatment and prophylaxis of adult patients and children suffering from UTI has shown good clinical efficacy and safety as published in 26 uncontrolled, in two earlier controlled and in one large postmarketing observational study including a total of more than 11,000 patients. This first IPD meta-analysis of four so far unpublished, prospective, randomized, comparative clinical studies with a total of 466 female patients with sporadic or recurrent uncomplicated UTI has demonstrated non-inferiority (10% non-inferiority margin) between treatment with nitroxoline versus controls (cotrimoxazole, norfloxacin). With a 5-day (sporadic UTI) and 10-day (recurrent UTI) treatment with nitroxoline 250 mg t.i.d. eradication of bacteriuria could be achieved in over 90% of the patients. The safety of nitroxoline was comparable with that of the controls. Adverse events, mainly gastrointestinal disorders and only a few allergic reactions, were reported only in 9.4% patients

treated with nitroxoline and 7.8% with the control drugs. Combining the vast clinical experience obtained from studies published earlier and non-inferiority of bacteriological efficacy with nitroxoline versus the controls as documented by this high quality IPD meta-analysis and considering the world wide increase of resistance of uropathogens against cotrimoxazole and fluoroquinolones, which has not been seen with nitroxoline despite clinical usage for more than 20 years, nitroxoline should be reconsidered as one of the first line antibiotics for the treatment of uncomplicated UTI.

Abbreviations

CFU: Colony forming units; CRF: Clinical report form; CTX: Cotrimoxazole; IPD: Individual patients' data; MIC: Minimal inhibitory concentration; mMITT: Modified microbiological intention to treat; mPP: Modified per protocol; n: Number; NFX: Norfloxacin; NTX: Nitroxoline; P: Prophylaxis; PP: Per protocol; SMX: Sulphamethoxazole; T: Therapy; UTI: Urinary tract infection; cUTI: Complicated urinary tract infection; rUTI: Recurrent urinary tract infection; uUTI: Uncomplicated urinary tract infection.

Competing interests

KG has relations to Basilea (investigator, consultant), Bionorica (investigator, consultant, speakers bureau, scientific publication), Boehringer Ingelheim (consultant), Cubist (consultant), DaiichiSankyo (speakers bureau, scientific publication), Dr. Reddy's (speakers bureau), Galenus (consultant), Leo Pharma (consultant, speakers bureau), MerLion (consultant, investigator, scientific publication), OM Pharma/Vifor (consultant, investigator, speakers bureau, scientific publication), Paratek (consultant), Pierre Fabre (consultant, scientific publication), Rempex Pharma (consultant), Rosen Pharma (consultant, investigator, scientific publication), Shionogi (consultant), Zambon (consultant, investigator, speakers bureau, scientific publication). HN has relations to Rosen Pharma (statistical consultant, data analysis). GiS is employee of Rosen Pharma, Blieskastel, Germany. GuS has no company relations.

Authors' contributions

GiS had the idea for the literature review and meta-analysis and performed the narrative literature search. KGN, GiS and HN developed the plan for the IPD meta-analysis. Data analysis was performed by HN. KGN was mainly responsible for the data presentation and the manuscript assisted by the other authors. GuS supervised the project and contributed to the manuscript as well. All authors read and approved the final manuscript.

Authors' information

1. Assoc. Professor of Urology of the Technical University Munich, Munich; priv. address: Karl-Bickler-Str. 44c, 94315 Straubing, Germany, e-mail: kurt@nabers.de; 2. Statistical Consulting & Data Analysis, Schlehdornweg 24, 07751 Jena, Germany, e-mail: niggemann@p-wert.de; 3. Rosen Pharma, Kirkele-Str.41, 66440 Blieskastel-Niederwürzbach, Germany, e-mail: gisela.stein@rosen-pharma.de; 4. Em. Professor of Internal Medicine of the University of Jena; priv. address: Von-Hase-Weg 22, 07743 Jena, Germany, e-mail: guenter.stein@med.uni-jena.de

Acknowledgements

The study was supported by Rosen Pharma GmbH, St. Ingbert, Germany. Andrea Pfeiffer, Markus Prasser, and Walter Wittershagen extracted the data from the individual patient's CRFs into the statistical data management files.

Author details

¹Department of Urology, Technical University of Munich, Ismaningerstr. 22, 81675 Munich, Germany. ²Statistical Consulting & Data Analysis, Schlehdornweg 24, 07751 Jena, Germany. ³Rosen Pharma, Kirkele-Str.41, 66440 Blieskastel, Germany. ⁴Department of Internal Medicine, University of Jena, Erlanger Allee 101, 07747 Jena, Germany.

Received: 2 March 2014 Accepted: 10 November 2014
Published online: 27 November 2014

References

1. Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. *Eur Urol* 2008, **54**:1164–1178.
2. Kahlmeter G: The ECO-Sens Projekt: a prospective, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens- interim report. *J Antimicrob Chem* 2000, **46**:15–22.
3. Kahlmeter G, Odén Poulsen H: Antimicrobial susceptibility of *Escherichia coli* from community-acquired urinary tract infections in Europe: the ECO-SENS study revisited. *Int J Antimicrob Agents* 2012, **39**:45–51.
4. Wagenlehner FME, Naber KG: Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. *Int J Antimicrob Agents* 2004, **23**:24–29.
5. Fisher JF, Newman CL, Sobel JD: Yeast in the urine: solutions for a budding problem. *Clin Infect Dis* 1995, **20**:183–189.
6. Bukhary ZA: Candiduria: a review of clinical significance and management. *Saudi J Kidney Dis Transpl* 2008, **19**:350–360.
7. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, Senger SS: Risk factors for extended-spectrum b-lactamase positivity in uropathogenic *Escherichia coli* isolated from community-acquired urinary tract infections. *Clin Microbiol Infect* 2010, **16**:147–151.
8. Lee S-J, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, Cho Y-H: Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean antimicrobial resistance monitoring system. *J Infect Chemother* 2011, **17**:440–446.
9. Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, Bjerklund Johansen T: Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. *World J Urol* 2013, **32**:791–801.
10. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *Clin Infect Dis* 1999, **29**:745–758.
11. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011, **52**:103–120.
12. Wagenlehner FME, Schmiemann G, Hoyme U, Fuenfstueck R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensieck W, Watermann D, Naber KG: Epidemiology, diagnostics, therapy and management of uncomplicated bacterial community acquired urinary tract infections in adults. [http://www.awmf.org/uploads/tx_szleitlinien/043-044_S3_Harnwegsinfektionen.pdf] (visited 16 Nov 2014)
13. Grabe M, Bjerklund Johansen TE, Botto H, Wullt B, Cek M, Naber KG, Pickard RS, Tenke P, Wagenlehner F: Guidelines on Urological Infections. Part 19. Arnhem, The Netherlands: European Association of Urology; 2014:1–107. ISBN 978-90-79754-65-6 [http://www.uroweb.org/gls/pdf/19%20Urological%20infections_LR.pdf] (visited 16 Nov 2014).
14. Kleemann A, Engel J, Reichert D, Kutscher B: *Pharmaceutical Substances. Syntheses, Patents Applications*. Stuttgart, New York: Thieme; 1999:1355–1356.
15. Sweetman SC: *Martindale. The Complete Drug Reference*. 34th edition. London: Pharmaceutical Press; 2004:238.
16. Rosen Pharma: Summary of Product Characteristics (SPC) of Nitroxoline Forte [Article in German]. [http://www.fachinfo.de/suche/fi/009370] (visited 16 Nov 2014)
17. Jacobs MR, Robinson RG, Koornhof HJ: Antibacterial activity of nitroxoline and sulphamethizole alone and in combination in urinary tract infections. *S Afr Med J* 1978, **54**:959–962.
18. Bourlioux P, Amgar A: Multicenter study of the resistance to seven antibiotics of pathogens recovered from urinary tract infections [Article in French]. *Sem Hôp Paris* 1988, **64**:86–90.
19. National Antibiotic Susceptibility Testing Committee (Germany): Nitroxoline. Rationale for the NAK Clinical Breakpoints. [http://www.nak-deutschland.org/tl_files/nak-deutschland/Nitroxoline_rationale_V_1.0_31012014.pdf] (visited 16 Nov 2014).
20. Bonissol C, Pua K, Stoiljkovic B: In vitro activity of nitroxoline on urogenital mycoplasmas [Article in French]. *Pathol Biol (Paris)* 1966, **34**:1001–1005.

21. Amgar A: Activity in vitro of urine samples from patients treated by nitroxoline against mycoplasmas. *J Chemother* 1989, **4**:226–228.
22. Hernández Molina JM, Llosá J, Ventosa A: In vitro activity of nitroxoline against clinical isolates of *Candida* species. *Mycoses* 1991, **34**:823–825.
23. Focht J, Noesner K: In-vitro activity of nitroxoline against *Candida* [Article in German]. *Extracta Urologica* 1995, **18**:26–27.
24. Lambert-Zechovsky N, Leveque B, Bingen E, Pillion G, Chapelle J, Mathieu H: Clinical study and effect of nitroxoline on fecal flora in children [Article in French]. *Pathol Biol (Paris)* 1987, **35**:669–672.
25. Kresken M, Körber-Irrgang B, on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy: In vitro activity of nitroxoline against urine isolates of *Escherichia coli* from the community: results of a German multicentre study [Abstract]. In *23rd European Congress of Clinical Microbiology and Infectious Diseases (23rd ECCMID): 27–30 April 2013; Berlin, Germany*. [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=160328&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASKEN_ID=900] (visited 16 Nov 2014)
26. Kresken M, Körber-Irrgang B: In vitro activity of nitroxoline against uropathogens other than *Escherichia coli* and impact of pH [Poster]. In *24th European Congress of Clinical Microbiology and Infectious Diseases (24th ECCMID): 10–13 May 2014; Barcelona, Spain*.
27. Cancet B, Amgar A: In vitro antifungal activity of nitroxoline. Preliminary clinical results [Article in French]. *Pathol Biol (Paris)* 1987, **35**:879–881.
28. Michel-Nguyen A, Nourrit J, Penaud A, Nicoli RM: Nitroxoline and traditional antifungal agents. Comparison of their antifungal activity against 238 yeast strains [Article in French]. *Bull Soc Fr Mycol Med* 1986, **15**:265–268.
29. Bourlioux P, Karam D, Amgar A, Perdiz M: Relationship between the chelating activity of nitroxoline, bacterial surface hydrophobicity and the reduction of bacterial adherence [Article in French]. *Pathol Biol (Paris)* 1989, **37**:600–604.
30. Pelletier C, Prognon P, Latrache H, Villart L, Bourlioux P: Microbiological effects of divalent metal ions interaction with nitroxoline [Article in French]. *Pathol Biol (Paris)* 1994, **42**:406–411.
31. Pelletier C, Prognon P, Bourlioux P: Roles of divalent cations and pH in mechanism of action of nitroxoline against *Escherichia coli* strains. *Antimicrob Agents Chemother* 1995, **39**:707–713.
32. Latrache H, Bourlioux P, Karrassi M, Zahir H, Hakkou A: Effects of subinhibitory concentrations of nitroxoline on the surface properties of *Escherichia coli*. *Folia Microbiol* 2000, **45**:485–490.
33. Fraser RSS, Creanor J: Rapid and selective inhibition of RNA synthesis in yeast by 8-hydroxyquinoline. *Eur J Biochem* 1974, **46**:67–73.
34. Karam D, Amgar A, Bourlioux P: Inhibition of bacterial adherence from uropathogenic *Escherichia coli* strains by the urine of patients treated by nitroxoline [Article in French]. *Pathol Biol (Paris)* 1988, **36**:452–455.
35. Bourlioux P, Botto H, Karam D, Amgar A, Camey M: Reduction of bacterial adherence by nitroxoline on epithelial cells and on urinary catheter surfaces [Article in French]. *Pathol Biol (Paris)* 1989, **37**:451–454.
36. Oliviero L, Perdiz M, Bourlioux P: Direct effect of nitroxoline in the reduction of bacterial adherence on urinary catheter [Article in French]. *Pathol Biol (Paris)* 1990, **38**:455–458.
37. Sobke A, Klinger M, Hermann B, Sachse S, Nietzsche S, Makarewicz O, Keller PM, Straube PW: The urinary antibiotic 5-nitro-8-hydroxyquinoline (nitroxoline) reduces the formation and induces the dispersal of *Pseudomonas aeruginosa* biofilms by chelation of iron and zinc. *Antimicrob Agents Chemother* 2012, **56**:6021–6025.
38. Bergogne-Berezin E, Berthelot G, Muller-Serieys C: Present status of nitroxoline [Article in French]. *Pathol Biol (Paris)* 1987, **35**:873–878.
39. Mrhar A, Kopitar Z, Kozjek F, Presl V, Karba R: Clinical pharmacokinetics of nitroxoline. *Int J Clin Pharmacol Biopharm* 1979, **17**:476–481.
40. Wagenlehner FME, Münch F, Pilatz A, Bärmann B, Weidner W, Wagenlehner CM, Straubinger M, Blenk H, Pfister W, Naber KG: Urinary antibacterial activity of Nitroxoline 250mg and Trimethoprim 200mg against uropathogens in healthy volunteers. *Antimicrob Agents Chemother* 2014, **58**:713–721.
41. Sorel RH, Snelleman C, Hulshoff A: High-performance liquid chromatographic analysis of nitroxoline in plasma and urine. *J Chromatogr* 1981, **222**:241–248.
42. Franz M: The treatment of urinary tract infections with nitroxoline [Article in German]. *Z Allg Med* 1992, **68**:526–530.
43. Kuss R, Rometti A: Efficacy of 5-nitro-8-hydroxyquinoline (A82) in urinary tract infections [Article in French]. *Extrait de la Presse Médicale* 1962, **23**:1131–1132.
44. Moreau L, Reveillaud R-J: A new urinary antifungal antibiotic [Article in French]. *Essais Cliniques Du A. 82. Extrait de la Vie Médicale* 1962, **43**:35.
45. von Rütte B, Delnon I: Experiences with drugs. Chronic urinary tract infection and its treatment with Nibiol [Article in German]. *Schweiz Med Wochenschr* 1968, **47**(98):1864–1868.
46. Uhlir O, Hnatek J, Hatala M: Laboratory and clinical evaluation of 5-NOK. In *Advances in Antimicrobial and Antineoplastic Chemotherapy. Progress in Research and Clinical Application*, Proceedings of the VIth International Congress of Chemotherapy, Prague, 1971. Volume I/1 Antimicrobial Chemotherapy I. Urban & Schwarzenberg, Munich, Berlin, Vienna. Edited by Hejzlár M, Semonský M, Masák S; 1972:1353–1354.
47. Allal A, Giraud J-R, Kamina P, de Tourris H: Contribution to the treatment of urinary tract infections in pregnancy [Article in French]. *L'Ouest Médical* 1973, **4**:439–444.
48. Bittard M, Colas J-M, Henry J-C: Current value of nitroxyquinoline in the treatment of urological infections [Article in French]. *J de Besançon* 1974, **10**(3):183–188.
49. Schlesinger E, Patsch R, Kraft M: Initial experience with 5-nitrooxyquinoline in the treatment of chronic urinary tract infection [Article in German]. *Zschr Urolog* 1975, **68**(6):429–434.
50. Aubert J: Significance of anti-bacterial prevention with Nibiol forte during urological instrumentations [Article in French]. *Ouest Médical* 1976, **29**(23):1762–1765.
51. Dufour A, Bollack C: Penetration of nitroxoline into prostatic tissue. A therapeutic trial [Article in French]. *J Urol Nephrol* 1979, **3**:207–212.
52. Lenzner A: Oral treatment with nitroxoline for fungal complaints of urinary tract [Article in German]. *Therapie Woche* 1983, **33**:1735–1738.
53. Schülke J, Sökeland J: Treatment of post operative urinary tract infection with Nitroxoline [Article in German]. *Prakt Arzt* 1984, **21**(25):1692–1696.
54. Sachse D: Therapy for chronically-recurrent urinary tract infection with nitroxoline [Article in German]. *Therapie Woche* 1984, **34**:228–230.
55. Demontrond D, Steinmetz P, Bernard PF: Treatment of 15 patients with nitroxoline for fungal urinary tract infections [Article in French]. *Bull Soc Fr Mycol Med* 1986, **XV**(2):307–310.
56. Frobert JL, Coupry A: Nibiol forte in the treatment of uncomplicated lower urinary tract infections in women [Article in French]. *Gazette Médicale* 1987, **94**(17):71–74.
57. Lecornu M: The use of a suspension of nitroxoline for the treatment of pediatric urinary tract infections [Article in French]. *Ouest Médical* 1974, **7**:715–717.
58. Roussel B, Dupouy D, Couchot J, Gomes H, Fandre M: Value of Nibiol suspension in the treatment of urinary tract infection in the infant and the child [Article in French]. *J des Médecins du Nord de l'Est* 1974, **2**:85–87.
59. Raynaud: Nibiol suspension in pediatrics [Article in French]. *Médecine Practicienne* 1974, **567**:59–60.
60. Luckel JC, Brochard A, Juif JG: Value of Nibiol suspension in urinary tract infections in children [Article in French]. *J Méd Strasbourg* 1975, **6**:545–548.
61. Viville C: Clinical trial of nitroxoline suspension [Article in French]. *Méd Gén Nord* 1975, **1**:63–65.
62. Chable JP, Dumas R, Jean R: Nitroxoline in treatment of urinary tract infections in children [Article in French]. *Bord Med* 1975, **3**:305–313.
63. Battin J: Use of nibiol suspension (nitroxoline) in pediatrics [Article in French]. *Bord Med* 1975, **13**:1597–1600.
64. Sorez J, Vanlaeys R, Lelong M: Influence of a suspension of nitroxoline (Nibiol) in childhood urinary tract infections [Article in French]. *Med Gen Nord* 1975, **2**:49–53.
65. Neimann N, Andre JL: Clinical trial of Nibiol (nitroxoline) suspension in urinary infections in the infant and child [Article in French]. *Med Gen Nord* 1975, **1**:90–96.
66. Machecourt D, Lebranchu Y, Bost M: Nitroxoline in treatment of urinary infections in children [Article in French]. *RMAF* 1976, **9**:347–351.
67. Schülke J: Are gyrase inhibitors always better? [Article in German]. *Therapie Woche* 1986, **36**(42):4294–4297.
68. Dodat H, Chavrier Y, Dyon JF, Aubert D, Galifer RB, Montupet P, Morisson-Lacombe G, Moscovici J, Valla J: Multicenter clinical study of nitroxoline versus cotrimoxazole for prevention of urinary tract infection in children [Article in French]. *Gazette Médicale* 1988, **95**(29):56–59.

69. WMA Declaration of Helsinki: **Ethical principles for medical research involving human subjects**. *Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 41st WMA General Assembly, Hong Kong, September 1989.* <http://www.wma.net/en/30publications/10policies/b3/index.html.pdf> (visited 16 Nov 2014)
70. Naber KG: **Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections**. *Int J Antimicrob Agents* 1999, **11**:189–196. discussion 213–216.
71. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, for the CONSORT Group: **Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement**. *JAMA* 2006, **295**:1152–1160.
72. Rabe-Hesketh S, Skrondal A: *Multilevel and Longitudinal Modeling Using Stata*. 3rd edition. College Station, TX: Stata Press; 2012.
73. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, McQuay HJ: **Assessing the quality of reports of randomized clinical studies: is blinding necessary?** *Contr Clin Trials* 1996, **17**:1–12.
74. Abraham NS, Moayyedi P, Daniels B, van Zanten JO: **Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia**. *Aliment Pharmacol Ther* 2004, **19**:631.
75. Cochrane Individual Participant Data (IPD) Meta-analysis Methods Group: **About IPD meta-analyses**. [<http://ipdmamg.cochrane.org/about-ipd-meta-analyses>] (visited 16 Nov 2014)
76. Stewart LA, Tierney JF: **To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data**. *Eval Health Prof* 2002, **25**:76–97.

doi:10.1186/s12879-014-0628-7

Cite this article as: Naber *et al.*: Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. *BMC Infectious Diseases* 2014 **14**:628.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

